-
公开(公告)号：EP4410836A1
公开(公告)日：2024-08-07
申请号：EP22875057.6
申请日：2022-09-29
申请人： Nanjing Shunxin Pharmaceuticals Co., Ltd. of Chiatai Tianqing Pharmaceutical Group , CHIA TAI TIANQING PHARMACEUTICAL GROUP CO., LTD.
发明人： YANG, Anqi , ZHANG, Xiquan , YU, Ding , LV, Peng , WANG, Xunqiang , TIAN, Xin , CHEN, Qin
IPC分类号： C07K16/28 , A61K39/395 , A61P35/00
CPC分类号： A61K39/395 , C07K16/28 , A61P35/00
摘要： An anti-CD47 antibody for combined treatment of a blood tumor. Provided are the use of the anti-CD47 antibody and a second therapeutic agent in the preparation of a drug for treating a blood tumor in a subject. Provided is a method for treating a blood tumor in a subject, comprising administering a therapeutically effective amount of the anti-CD47 antibody and the second therapeutic agent to a subject. Also provided are a pharmaceutical combination comprising the anti-CD47 antibody and the second therapeutic agent, and a kit.
-
公开(公告)号：EP4302763A1
公开(公告)日：2024-01-10
申请号：EP22762608.2
申请日：2022-03-03
发明人： FENG, Fan , YU, Ding , WANG, Xunqiang , ZHANG, Xiquan , BAI, Yanfeng , YANG, Chaoqiang , ZHANG, Yuying
IPC分类号： A61K31/565 , C07D403/14 , A61P35/00
摘要： The present disclosure relates to a combined pharmaceutical composition containing a CDK4/6 inhibitor and a use thereof, and specifically relates to a combined pharmaceutical composition comprising a compound of formula (I) or a pharmaceutically acceptable salt thereof and fulvestrant. The present disclosure further relates to a use of the combined pharmaceutical composition in treating breast cancer. The combined pharmaceutical composition of the present disclosure produces better therapeutic effects in reducing tumor growth or even eliminating tumors.
-
公开(公告)号：EP4159238A1
公开(公告)日：2023-04-05
申请号：EP21817364.9
申请日：2021-06-01
申请人： CHIA TAI TIANQING PHARMACEUTICAL GROUP CO., LTD. , Tianjin Medical University Cancer Institute and Hospital
发明人： ZHANG, Xiquan , WANG, Xunqiang , YU, Ding , LIU, Tao , ZHAN, Xiaole , WU, Naiying
IPC分类号： A61K39/395 , C07D215/22 , C07K16/28 , A61P35/00
摘要： Provided are a combined pharmaceutical composition of an anti-PD-L1 antibody and a c-Met kinase inhibitor, specifically, a combined pharmaceutical composition of an anti-PD-L1 antibody and N-(4-((7-((1-(cyclopentylamino)cyclopropyl)methoxy)-6-methoxyquinolin-4-yl)oxy)-3-fluorophenyl)-N-(4-f luorophenyl)cyclopropane-1,1-dicarboxamide, and the use of the combined pharmaceutical composition in the treatment of cancers, in particular, gastric cancer or liver cancer.
-
公开(公告)号：EP4431097A1
公开(公告)日：2024-09-18
申请号：EP22892074.0
申请日：2022-11-11
发明人： ZHAO, Qian , WANG, Xunqiang , ZHANG, Xiquan , YU, Ding
IPC分类号： A61K31/498 , A61K31/4709 , A61P7/04 , A61P37/00
CPC分类号： A61K31/498 , A61P37/00 , A61K31/4709 , A61P7/04
摘要： The present invention relates to a use of a quinolinone derivative in treatment of immune thrombocytopenia, and in particular to a use of a compound of formula (I) or a pharmaceutically-acceptable salt or pharmaceutical composition thereof in treatment of immune thrombocytopenia.
-
公开(公告)号：EP4144371A1
公开(公告)日：2023-03-08
申请号：EP21795809.9
申请日：2021-04-30
发明人： YANG, Anqi , ZHANG, Xiquan , WANG, Xunqiang , YU, Ding , LI, Lin , WANG, Rongliang
IPC分类号： A61K39/395 , A61K31/4709 , A61P35/00
摘要： The present invention relates to the field of biomedicines. Disclosed is a combination drug for treating kidney cancer, comprising an anti-PD-L1 antibody and anlotinib or a pharmaceutically acceptable salt thereof. The present invention also provides use of the combination drug in the preparation of drugs for treating kidney cancer.
-
公开(公告)号：EP4119557A1
公开(公告)日：2023-01-18
申请号：EP21767461.3
申请日：2021-03-10
发明人： YANG, Anqi , ZHANG, Xiquan , WANG, Xunqiang , YU, Ding , GUO, Fangfang
IPC分类号： C07D471/04 , A61K31/519 , A61P35/00
摘要： The present invention belongs to the field of medicinal chemistry, and relates to a pharmaceutical combination comprising a pyridino[1,2-a]pyrimidinone compound. In particular, the pharmaceutical combination comprises a compound of formula I or a pharmaceutically acceptable salt thereof and a fulvestrant or a pharmaceutically acceptable salt thereof. The present invention also relates to the independent use of the pharmaceutical combination, or the compound of formula I or a pharmaceutically acceptable salt thereof in the treatment of breast cancer patients.
-
公开(公告)号：EP4410777A1
公开(公告)日：2024-08-07
申请号：EP22872243.5
申请日：2022-09-27
发明人： FENG, Fan , YU, Ding , ZHANG, Xiquan , WANG, Yueting
IPC分类号： C07D231/56 , C07D401/14 , C07D403/14 , A61K31/416 , A61K31/44 , A61K31/445 , A61K31/506 , A61P35/00
CPC分类号： A61K31/416 , A61K31/445 , A61K31/44 , A61K31/506 , A61P35/00 , C07D231/56 , C07D401/14 , C07D403/14
摘要： The present disclosure relates to a combined pharmaceutical composition of a CDK4/6 inhibitor and an aromatase inhibitor, and the use thereof in the treatment of breast cancer. Compared with separate administration of any agent in the composition, the combined pharmaceutical composition of the present disclosure yields a better therapeutic effect on slowing tumor growth or even eliminating tumors.
-
8.发明公开
公开(公告)号：EP4361152A1
公开(公告)日：2024-05-01
申请号：EP22827576.4
申请日：2022-06-21
申请人： CHIA TAI TIANQING PHARMACEUTICAL GROUP CO., LTD. , Shouyao Holdings (Beijing) Co., Ltd. , Lianyungang Runzhong Pharmaceutical Co., Ltd.
发明人： TU, Lifan , ZHANG, Xiquan , WANG, Xunqiang , YU, Ding , HUANG, Jianqiang
IPC分类号： C07D487/04 , A61K31/519 , A61P37/06
CPC分类号： C07D487/04 , A61K31/519 , A61P37/06
摘要： The present invention relates to the use of a pyrrolopyrimidine compound and a pharmaceutical composition thereof for treating chronic graft versus host disease, and particularly relates to the use of a compound of formula (I), a stereoisomer thereof, or a pharmaceutically acceptable salt thereof, and a pharmaceutical composition thereof for treating chronic graft versus host disease.
-
公开(公告)号：EP4119562A1
公开(公告)日：2023-01-18
申请号：EP21767840.8
申请日：2021-03-09
申请人： CHIA TAI TIANQING PHARMACEUTICAL GROUP CO., LTD. , Lianyungang Runzhong Pharmaceutical Co., Ltd. , Shouyao Holdings (Beijing) Co., Ltd.
发明人： LIANG, Hongming , ZHANG, Xiquan , WANG, Xunqiang , YU, Ding , WANG, Dong , GE, Qi , WANG, Zhao , WANG, Yini
IPC分类号： C07D487/04 , A61K31/519 , A61P7/00
摘要： The present invention relates to use of a pyrrolopyrimidine compound for treating hemophagocytic syndrome, and particularly relates to use of a compound of formula (I), a stereoisomer thereof, or a pharmaceutically acceptable salt thereof, and a pharmaceutical composition thereof for treating hemophagocytic syndrome.
-
公开(公告)号：EP3939610A1
公开(公告)日：2022-01-19
申请号：EP20774316.2
申请日：2020-03-13
申请人： CHIA TAI TIANQING PHARMACEUTICAL GROUP CO., LTD. , Nanjing Shunxin Pharmaceutical Co., Ltd. of Chiatai Tianqing Pharmaceutical Group
发明人： WANG, Shanchun , WANG, Xunqiang , YU, Ding , LIU, Wenwen , SHU, Chao , FAN, Mengxue
IPC分类号： A61K39/395 , A61K31/4709 , A61P35/00
摘要： The present invention relates to the field of biomedicine and relates to a combined pharmaceutical composition used for treating small cell lung cancer, the composition comprising an anti-PD-L1 antibody and anlotinib, and having good anti-small cell lung cancer activity.
-
-
-
-
-
-
-
-
-
搜索结果
14 条记录 (耗时 0.018 秒)
